Group One Trading
CRDL

Group One Trading’s Cardiol Therapeutics CRDL Stock Holding History

Group One Trading’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,534
Closed -$1.61K – 8269
2025
Q3 		$1.64K Sell
1,534
-6,179
-80% -$7.5K ﹤0.01% 7956
2025
Q2 		$10.5K Sell
7,713
-733
-9% -$853 ﹤0.01% 6689
2025
Q1 		$8.19K Buy
8,446
+3,139
+59% +$3.85K ﹤0.01% 6390
2024
Q4 		$6.79K Sell
5,307
-19,533
-79% -$32.9K ﹤0.01% 6288
2024
Q3 		$49.2K Sell
24,840
-3,452
-12% -$7.16K ﹤0.01% 4661
2024
Q2 		$57.1K Buy
28,292
+24,625
+672% +$52.3K ﹤0.01% 4423
2024
Q1 		$6.64K Hold
3,667
– – ﹤0.01% 6071
2023
Q4 		$3.08K Buy
3,667
+2,000
+120% +$1.7K ﹤0.01% 6689
2023
Q3 		$1.53K Buy
1,667
+1,666
+166,600% +$1.59K ﹤0.01% 7120
2023
Q2 		$1 Hold
1
– – ﹤0.01% 7572
2023
Q1 		$0 Hold
1
– – ﹤0.01% 7314
2022
Q4 		$1 Buy
+1
New +$1 ﹤0.01% 7127

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading's CRDL Position: Q4 2025 in Review

Group One Trading sold out of Cardiol Therapeutics (CRDL) in Q4 2025, closing a stake of 1,534 shares — an estimated $1.61K sold.

Group One Trading first reported a position in CRDL in Q4 2022 and held it in 12 quarters. The position peaked at $57.1K in Q2 2024. 41 funds tracked by Wall St. Rank hold CRDL as of Q4 2025.

  • Group One Trading reported no remaining Cardiol Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Group One Trading sold 1,534 Cardiol Therapeutics shares in Q4 2025, an estimated $1.61K.
  • Group One Trading first reported a position in Cardiol Therapeutics in Q4 2022 and held it in 12 quarters.
  • Group One Trading's Cardiol Therapeutics position peaked at $57.1K in Q2 2024.
  • 41 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q4 2025.

Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.